A dual agonist hitting both the GIP and GLP-1 receptors. Head-to-head trials show greater average weight reduction than single-agonist GLP-1s, at the cost of a similar gastrointestinal side-effect profile.
FDA-approved (Mounjaro, Zepbound).
Ranges compiled from published protocols, not a clinical guideline. Convert a dose into syringe units with the dosage calculator.
This page summarises how much a compound has been studied. A high publication count is not evidence that something works, is safe, or is legal to obtain where you live. Consult a qualified healthcare provider before acting on anything here.
Our mission is to make peptide research clear, credible, and usable for people who refuse to rely on hype.